FTC breast enhancement case
This article was originally published in The Tan Sheet
J. Michael Ernest, PhD, Isis Breast Enhancement System developer, agrees to settle FTC charges he made deceptive statements in print, radio, TV, Internet ads for the supplement/topical cream combo, commission says Jan. 22. Proposed stipulated final order requires Ernest to "have competent and reliable scientific evidence" before making any claims about Isis, other products. Settlement follows recent case brought by FTC against Isis marketer Vital Dynamics, which was settled in December (1"The Tan Sheet" Jan. 6, 2003, p. 19)...
You may also be interested in...
Vital Dynamics promoted its Isis Breast Enhancement System as free of side effects after receiving "hundreds of reports of negative side effects," according to a Federal Trade Commission complaint
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.